NASDAQ:ALDX
Aldeyra Therapeutics Stock News
$3.27
+0.190 (+6.17%)
At Close: Mar 28, 2024
Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOA
08:28am, Monday, 19'th Sep 2022
Shares have bucked weakness in the biotech sector and risen 60% year to date. Dry eye disease is a lucrative indication for reproxalap (albeit with generic competition) and differentiation is apparent
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?
01:55pm, Monday, 15'th Aug 2022 Zacks Investment Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying
12:37pm, Monday, 08'th Aug 2022 Benzinga
Although US stocks closed mixed on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock
Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript
07:00am, Sunday, 07'th Aug 2022 The Motley Fool
ALDX earnings call for the period ending June 30, 2022.
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2022 Results - Earnings Call Transcript
02:01pm, Friday, 05'th Aug 2022
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President & Chi
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
02:25am, Thursday, 04'th Aug 2022
Reproxalap seems poised for FDA approval for dry eye disease. Therapy has clear practical advantages over Restasis and Xiidra.
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Friday, August 5, 2022 to report financial results for the quarter en
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
02:53pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals
01:05pm, Wednesday, 13'th Jul 2022
Aldeyra's (ALDX) vehicle-controlled crossover study evaluating 0.25% reproxalap ophthalmic solution for the treatment of dry eye disease meets primary endpoints. Shares up.
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
08:59am, Wednesday, 13'th Jul 2022 Benzinga
Gainers
Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.
Aldeyra's Reproxalap Hits Primary Goals In Dry Eye Disease Chamber Crossover Trial
09:03am, Tuesday, 12'th Jul 2022
Aldeyra Therapeutics Inc (NASDAQ: ALDX) achieved the primary endpoints in a crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate for dry eye disea
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, July 12, 2022, at 8:00 a.m. (ET) to report
Why Aldeyra Therapeutics' Shares Are Soaring Today?
09:47am, Wednesday, 08'th Jun 2022
Aldeyra Therapeutics Inc's (NASDAQ: ALDX) Phase 3 TRANQUILITY-2 trial of reproxalap for dry eye disease has achieved the primary endpoint. Reproxalap was statistically superior to the vehicle for ea
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Wednesday, June 8, 2022, at 8:00 a.m. (ET) to provi
Aldeyra Therapeutics to Present at H.C. Wainwright Global Investment Conference
04:05pm, Monday, 23'rd May 2022
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today ann